Litcius/Paper detail

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

Alison Tree, Victoria Hinder, Andrew Chan, Shaun Tolan, Peter Ostler, H. van der Voet, Kiran Kancherla, Andrew Loblaw, Olivia Naismith, Suneil Jain, Alexander Martin, Derek Price, Douglas Brand, William Chu, Aileen Duffton, Paul Kelly, Brian O’Neill, John Staffurth, Giuseppe Sasso, Julia Pugh, Georgina Manning, Stephanie Brown, Stephanie Burnett, Clare Griffin, Emma Hall, Nicholas van As, Imtiaz Ahmed, Mark Beresford, Thomas Bird, Jennifer Branagan, Patryk Brulinski, Philip Camilleri, Ananya Choudhury, Prantik Das, Omar Din, Daniel Ford, Victoria Ford, John Frew, Peter Jenkins, Bartlomiej Kurec, Carolynn Lamb, Eric Lee, Anna Lydon, Maria Martinou, John McGrane, Alina Mihai, Vinod Mullassery, Sarah Needleman, Ashok Nikapota, Nikhil Oommen, Sophie Otter, Miguel Panades, Dominique Parslow, Rachel Pearson, Rakeshkumar K. Raman, Mausam Singhera, Yae-Eun Suh, Aravindhan Sundaramurthy, Jacob Tanguay, Kamalram Thippu Jayaprakash, Hans Van Der Voet, Salil Vengalil, Ramachandran Venkitaraman, Robert Wade, Georgina Walker, Paula Wells

2025The Lancet Oncology26 citationsDOIOpen Access PDF

Topics & Concepts

Prostate cancerMedicineRadiation therapyToxicityOncologyProstateInternal medicineCancerProstate Cancer Diagnosis and TreatmentAdvanced Radiotherapy TechniquesProstate Cancer Treatment and Research